Pallavi Madhiraju, Author at PharmaDeviceNews

Why Tempus AI’s Lens upgrade matters for precision oncology drug development

Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.

Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.